TABLE 3.
Univariate analyses of the association between clinical characteristics and the risk of ARDS or death in 53 kidney transplant patients with SARS-CoV-2 infection
| Variable | Outcome ARDS | Outcome death | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Sex | 0.52 (0.12-1.99) | .35 | 0.62 (0.15-2.74) | .51 |
| Age (>60 vs ≤60) | 1.47 (0.5-4.41) | .49 | 2.06 (0.62-7.29) | .24 |
| History of hypertension | 0.83 (0.21-3.18) | .79 | 0.38 (0.08-1.3) | .93 |
| History of cardiac disease | 1.57 (0.39-6.89) | .53 | 1.94 (0.43-8.15) | .37 |
| History of DVT | 3.13 (0.37-65.6) | .34 | 2.77 (0.31-25.1) | .33 |
| History of diabetes | 3.23 (0.81-16.34) | .12 | 1.61 (0.36-6.48) | .51 |
| Number of comorbidities (0-1 vs >1) | 0.94 (0.3-3) | .92 | 0.96 (0.25-3.34) | .95 |
| CNIs last follow-up | 1.63 (0.25-13.2) | .61 | 5.1 (0.26-98) | .99 |
| Cyclosporin last follow-up | 0.39 (0.11-1.26) | .122 | 0.43 (0.09-1.64) | .24 |
| Tacrolimus last follow-up | 2.77 (0.91-8.9) | .077 | 4 (1.1-19.7) | .05 |
| mTORi last follow-up | 0.96 (0.16-5.64) | .96 | 0.47 (0.02-3.3) | .51 |
| MMF last follow-up | 1.25 (0.41-3.81) | .7 | 2.23 (0.63-9.2) | .23 |
| Low dose steroids last follow-up | 1.7 (0.57-5.19) | .343 | 1.8 (0.53-6.71) | .36 |
| Baseline creatinine (≤2 vs >2 mg/dL) | 1.37 (0.46-4.2) | .58 | 1.03 (0.29-3.56) | .96 |
| Age transplant (>10 vs ≤10 y) | 0.37 (0.12-1.1) | .078 | 0.5 (0.13-1.69) | .28 |
| Cough at disease onset | 1.17 (0.39-3.5) | .78 | 1.76 (0.53-6.24) | .36 |
| Pharyngitis at disease onset | 6.9 (0.76-61.7) | .09 | 2.06 (0.36-10.7) | .39 |
| Shortness of breath at disease onset | 5.9 (1.6-29.1) | .015 | 7.75 (2.1-32.2) | .003 |
| Myalgia or fatigue at disease onset | 1.25 (0.4-4) | .703 | 0.6 (0.14-2.14) | .45 |
| Gastrointestinal symptoms at disease onset | 0.21 (0.04-1.1) | .07 | 0.26 (0.01-1.62) | .22 |
| Chest X-ray (bilateral infiltrates vs unilateral or no infiltrates) | 1.7 (0.46-6.7) | .44 | 3.24 (0.68-23.7) | .18 |
| Time from symptoms to antiviral (>5 vs ≤5 d) | 0.82 (0.22-2.95) | .76 | 0.8 (0.20-3) | .74 |
| Antiviral therapy | 2.38 (0.78-7.6) | .133 | 1.45 (0.43-5.43) | .56 |
| Hydroxychloroquine | 1.56 (0.46-5.54) | .48 | 0.98 (0.26-4.2) | .98 |
Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; CNI, calcineurin inhibitor; DVT, deep vein thrombosis; MMF, mofetil mycophenolate; mTORi, inhibitors of the mammalian target of rapamycin; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Bold values: statistically significant.